Q-omics provides the consensus-scored LYPLA2P3 profile across patient tissues and cancer cell-line models. LYPLA2P3 expression is associated with patient survival in 6 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, LYPLA2P3 is differentially expressed in 2, with the highest sampling consensus in KIRC. Additionally, LYPLA2P3 RNA expression shows 6,367 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight KIRC, and STAD as cancer lineages where LYPLA2P3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for LYPLA2P3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes LYPLA2P3 survival associations across molecular data types. LYPLA2P3 RNA expression shows survival associations in the most cancer types (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible LYPLA2P3 RNA expression–survival associations across cancer types. High LYPLA2P3 expression shows unfavorable associations in PAAD, TGCT, READ, STAD and HNSC, but favorable associations in KIRC. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .001). Together, the overview and detailed table identify KIRC as the clearest survival context for LYPLA2P3 RNA expression.
This table summarizes LYPLA2P3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 2. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for LYPLA2P3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. LYPLA2P3 shows higher tumor expression in KIRC and KIRP. The KIRC box plot shows higher LYPLA2P3 RNA expression in tumor versus normal tissue (log2 FC = +0.325, t-test p < 0.001).
This table shows molecular features associated with LYPLA2P3 in patient tissues and cancer cell lines. In patient samples, LYPLA2P3 shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set.
